These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17645811)

  • 21. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
    de Portu S; Citarella A; Cammarota S; Menditto E; Mantovani LG
    Clin Exp Hypertens; 2011; 33(3):174-8. PubMed ID: 21466388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation.
    Hogan TJ; Elliott WJ; Seto AH; Bakris GL
    Pharmacoeconomics; 2002; 20(1):37-47. PubMed ID: 11817991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
    Seng WK; Hwang SJ; Han DC; Teong CC; Chan J; Burke TA; Carides GW; Choi YJ
    Nephrology (Carlton); 2005 Oct; 10(5):520-4. PubMed ID: 16221106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
    Herman WH; Shahinfar S; Carides GW; Dasbach EJ; Gerth WC; Alexander CM; Cook JR; Keane WF; Brenner BM
    Diabetes Care; 2003 Mar; 26(3):683-7. PubMed ID: 12610022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; de Alvaro F;
    Nefrologia; 2004; 24(3):231-8. PubMed ID: 15283313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.
    Erickson KF; Chertow GM; Goldhaber-Fiebert JD
    Ann Intern Med; 2013 Sep; 159(6):382-9. PubMed ID: 24042366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. To treat or not to treat? Cost-effectiveness of ace inhibitors in non-diabetic advanced renal disease - a Dutch perspective.
    Adarkwah CC; Gandjour A; Akkerman M; Evers S
    Kidney Blood Press Res; 2013; 37(2-3):168-80. PubMed ID: 23689440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of end stage renal disease treatment.
    de Wit GA; Ramsteijn PG; de Charro FT
    Health Policy; 1998 Jun; 44(3):215-32. PubMed ID: 10182294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nitrendipine in patients with end-stage renal disease and hypertension.
    Bambauer R; Jutzler GA; Weber U; Walter R; Keller HE
    J Cardiovasc Pharmacol; 1988; 12 Suppl 4():S133-5. PubMed ID: 2468856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modelling the Cost-Effectiveness of Delaying End-Stage Renal Disease.
    de Vries EF; Rabelink TJ; van den Hout WB
    Nephron; 2016; 133(2):89-97. PubMed ID: 27270045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antihypertensive effect of nitrendipine in the hypertensive patient with renal impairment.
    Ruilope LM; Araque A; Lahera V; Suarez C
    Ren Fail; 1993; 15(3):359-63. PubMed ID: 8516491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A simulation model to estimate cost-offsets for a disease-management program for chronic kidney disease.
    Gandjour A; Tschulena U; Steppan S; Gatti E
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):341-7. PubMed ID: 25434825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of antihypertensive treatment in patients 80 years of age or older in Switzerland: an analysis of the HYVET study from a Swiss perspective.
    Szucs TD; Waeber B; Tomonaga Y
    J Hum Hypertens; 2010 Feb; 24(2):117-23. PubMed ID: 19536166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risks and costs of end-stage renal disease after heart transplantation.
    Hornberger J; Best J; Geppert J; McClellan M
    Transplantation; 1998 Dec; 66(12):1763-70. PubMed ID: 9884274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The economic implications of non-adherence after renal transplantation.
    Cleemput I; Kesteloot K; Vanrenterghem Y; De Geest S
    Pharmacoeconomics; 2004; 22(18):1217-34. PubMed ID: 15606228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is the best treatment for slowing the progression to end-stage renal disease (ESRD) in African Americans with hypertensive nephropathy?
    McConaghy JR
    J Fam Pract; 2001 Sep; 50(9):744. PubMed ID: 11674903
    [No Abstract]   [Full Text] [Related]  

  • 39. [Progress of diagnosis and treatment of hypertensive renal damage by Chinese medicine].
    Liu W; Xiong XJ; Wang J
    Zhongguo Zhong Yao Za Zhi; 2014 Jan; 39(1):14-9. PubMed ID: 24754161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Employer-paid nonmedical costs for patients with diabetes and end-stage renal disease.
    Kamal-Bahl SJ; Pantely S; Pyenson B; Alexander CM
    Prev Chronic Dis; 2006 Jul; 3(3):A83. PubMed ID: 16776884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.